The Delhi Drug Control Administration (DCA) has issued a stern advisory to chemist and druggist associations in the National Capital Territory (NCT) to curb the misuse of pregabalin and tapentadol formulations. This move comes in response to rising concerns over the abuse of these drugs, which are being misused for intoxication or addiction. The advisory, issued on August 14, 2025, urges chemists to halt the over-the-counter (OTC) sale of these drugs and maintain strict compliance with regulatory guidelines.

Key highlights

Concerns over misuse of pregabalin and tapentadol

• Pregabalin, an anticonvulsant and neuropathic pain medication, is being misused for its psychoactive effects.

• Tapentadol, a synthetic opioid analgesic, is also being abused, raising alarms among health authorities.

Immediate action to prevent OTC sale

• Retail chemists are instructed to stop the OTC sale of pregabalin and tapentadol formulations.

• The advisory stresses the risk of addiction and abuse posed by these drugs and calls for stricter controls.

Regulatory compliance and accountability

• Chemists are urged to keep accurate records of their stock and adhere to the Drugs Rules, 1945.

• Any violations will lead to stringent legal action by the DCA.

Wider awareness campaign

• Chemist associations have been asked to circulate the advisory to all their members and ensure compliance.

• The DCA seeks to spread awareness of the issue and prevent misuse across the industry.

National concern over online drug sales

• The All India Organization of Chemists and Druggists (AIOCD) has raised concerns about the online sale of pregabalin, urging the Union Home Minister to intervene.

• States like Haryana have also taken action, with recent raids uncovering large quantities of pregabalin and tapentadol being illegally distributed.

The advisory from the Delhi DCA is part of a broader effort to tackle the growing misuse of prescription drugs and ensure public safety. By curbing the OTC sale of these substances, authorities hope to reduce addiction rates and prevent illegal distribution, particularly through online platforms. Retail chemists are urged to uphold their ethical responsibilities and comply with the new regulations to protect consumer health.